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Establishing a clinical phenotype for
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disease – study protocol
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Abstract
Background: Surveys using traditional measures of nutritional status indicate that muscle wasting is common
among persons with end-stage kidney disease (ESKD). Up to 75% of adults undergoing maintenance dialysis show
some evidence of muscle wasting. ESKD is associated with an increase in inflammatory cytokines and can result in
cachexia, with the loss of muscle and fat stores. At present, only limited data are available on the classification of
wasting experienced by persons with ESKD. Individuals with ESKD often exhibit symptoms of anorexia, loss of lean
muscle mass and altered energy expenditure. These symptoms are consistent with the syndrome of cachexia
observed in other chronic diseases, such as cancer, heart failure, and acquired immune deficiency syndrome. While
definitions of cachexia have been developed for some diseases, such as cardiac failure and cancer, no specific
cachexia definition has been established for chronic kidney disease. The importance of developing a definition of
cachexia in a population with ESKD is underscored by the negative impact that symptoms of cachexia have on
quality of life and the association of cachexia with a substantially increased risk of premature mortality. The aim of
this study is to determine the clinical phenotype of cachexia specific to individuals with ESKD.
Methods: A longitudinal study which will recruit adult patients with ESKD receiving haemodialysis attending a
Regional Nephrology Unit within the United Kingdom. Patients will be followed 2 monthly over 12 months and
measurements of weight; lean muscle mass (bioelectrical impedance, mid upper arm muscle circumference and tricep
skin fold thickness); muscle strength (hand held dynamometer), fatigue, anorexia and quality of life collected. We will
determine if they experience (and to what degree) the known characteristics associated with cachexia.
Discussion: Cachexia is a debilitating condition associated with an extremely poor outcome. Definitions of cachexia
in chronic illnesses are required to reflect specific nuances associated with each disease. These discrete cachexia
definitions help with the precision of research and the subsequent clinical interventions to improve outcomes for
patients suffering from cachexia. The absence of a definition for cachexia in an ESKD population makes it particularly
difficult to study the incidence of cachexia or potential treatments, as there are no standardised inclusion criteria for
patients with ESKD who have cachexia. Outcomes from this study will provide much needed data to inform
development and testing of potential treatment modalities, aimed at enhancing current clinical practice, policy
and education.
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Background
Cachexia is “a complex metabolic syndrome associated
with underlying illness and characterised by muscle loss,
with or without loss of fat” [8]. It is a common syndrome
associated with chronic illness and has been defined in
the general population as weight loss of at least 5%
in ≤12 months or body mass index (BMI) < 20 kg/m2
plus three of the following five features: decreased
muscle strength; fatigue; anorexia; low fat-free mass
index; abnormal biochemistry (increased inflammatory
markers [C-reactive protein (CRP) > 5 mg/L], anaemia
[haemoglobin < 120 g/L] and low serum albumin [< 32 g/L]
[8]. To date, research has not explored the impact of cach-
exia in end-stage kidney disease (ESKD) but studies into
cachexia in other chronic illness have demonstrated the
devastating holistic impact it can have on patients, decreas-
ing physical function and quality of life [26] and shortening
survival [9, 30].
Research within a haemodialysis ESKD population has
established that weight stable patients survive longer
than those with weight loss [28]. Additionally, it is
known that wasting/cachexia occurs in up to 75% of
ESKD patients on haemodialysis [14]. However, despite
the high prevalence of cachexia in haemodialysis patients
there has been relatively little research specifically
targeted to this at risk population] [14]. For “renal cach-
exia” there are no standardised definitions or inclusion
criteria to help inform practice or research [25]. Thus,
the clinical management of cachexia in persons with
ESKD is challenging [14]. In part, this is due to the diffi-
culty discriminating cachexia from other causes of mal-
nutrition and weight loss [23]. For persons with ESKD
there is now greater emphasis on defining clinical
markers for Protein Energy Wasting (PEW) which pre-
cedes cachexia and specialised diagnostic tools are being
developed and tested [5, 16] Cachexia is seen as a severe
form of PEW [11, 13], however it is important to be able
to clinically differentiate between cachexia and PEW as
each may require distinct management strategies; such
discrimination may also be important when defining tar-
get groups for future trials of novel pharmacological or
nutritional interventions [21].
In summary, there remains limited consensus on the
defining characteristics of renal cachexia partly due to
limited epidemiological research on this syndrome in
ESKD. Although there is improved understanding of the
mechanisms underpinning cachexia in ESKD [27], fur-
ther research in this area and planning targeted clinical
interventions is hampered by the absence of an accurate
disease-specific cachexia phenotype in ESKD [7]. A gen-
eric definition of cachexia in chronic illness is available
[8] but the associated diagnostic criteria are not specific
to ESKD. The necessity to re-model this definition in
specific diseases is well recognised within the literature
([10]: [14]). Indeed, where this has been done in cancer,
it has led to a consensus definition and classification sys-
tem [1, 10], clinical practice guidelines [20] and has
made a positive impact to clinical management, research
study design, policy and also patient and professional
education. There is a pressing need to robustly define
the clinical phenotype of renal cachexia to help target
supportive measures for this population [6, 17].
Methods/design
Aim and objectives
The aim of this study is to determine the clinical pheno-
type of cachexia specific to individuals with ESKD.
The objectives of the study are to:
 Identify the prevalence of cachexia in ESKD patients
receiving haemodialysis
 Determine the percentage of ESKD patients
receiving haemodialysis who experience the known
characteristics of cachexia (how many and to what
degree)
 Develop a definition of cachexia specific to this
ESKD population.
Study population
This is a longitudinal study which will run over 2 years.
All patients with ESKD who receive haemodialysis
and attend a single Regional Nephrology Unit within the
United Kingdom, will be eligible for inclusion into this
study to determine if they experience (and to what de-
gree) the known characteristics associated with cachexia
(Table 1). Key factors, such as: primary renal disease; co-
morbidities (eg Charlson Comorbidity Index); recent
hospitalisation (within 3 months); drugs (particularly ste-
roids, erythropoietin stimulating agents and immuno-
suppressive agents); urea clearance; residual renal
function; and dialysis vintage will also be recorded.
The recruiting regional nephrology unit provides care
to approximately 250 chronic haemodialysis patients per
annum. Recruitment will take place over 7 months, with
Table 1 Characteristics of Cachexia [8, 14]
Unintentional oedema free weight loss ≥ 5% in 6 months or ≥ 10%
12 months (in the absence of documented weights, BMI < 20 kg/m2)
and in the absence of starvation.
Plus three of the following five criteria:
1) Decreased muscle strength(lowest tertile);
2) Fatigue (physical and/or mental weariness resulting from exertion not
merely post-dialysis fatigue);
3) Anorexia;
4) Lean tissue depletion (in relation to aged /gender normative data)
5) Abnormal biochemistry: increased inflammatory markers [CRP > 5 mg/L];
anaemia [haemoglobin < 120 g/L]; low serum albumin [< 32 g/L
bromocresol green].
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an expected recruitment rate of 145 patients. Suitable
patients will be identified via inpatient wards and out-
patient units at the recruiting regional nephrology unit.
Inclusion/exclusion criteria are outlined below. Once
recruited patients will be monitored for 1 year (or time to
death if < 1 year).
Data collection
This study is ‘ongoing’ and is currently carrying out
recruitment. All measures will be assessed at baseline and
will be repeated every 2 months for 12 months or until
death (Fig. 1). Patients will be asked to complete validated
tools to determine fatigue, quality of life and anorexia. We
will measure: weight; lean muscle mass (bioelectrical im-
pedance analysed via vector analysis, mid upper arm
muscle circumference - from measures of mid arm cir-
cumference and tricep skin fold thickness); muscle
strength (hand held dynamometer); and interrogate rou-
tine monthly clinical blood tests for abnormal biochemis-
try (Table 1).
Any dialysis unit is a busy clinical environment and
patients attending for haemodialysis three times per
week do not want to be delayed in entering or leaving
the dialysis unit. Thus it is imperative that the study
does not over burden the clinical area or participants.
We have worked closely with the clinical team to plan
how we will collect data from patients so as not to inter-
rupt the clinical flow or delay the patient unnecessarily
when they have completed a dialysis session. Where pos-
sible routinely collected clinical data will be used e.g.
Fig. 1 Recruitment and follow up diagram
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pre- and post-dialysis blood samples, weight pre- and
post-dialysis. We will ask patients (or help patients) to
complete the tools measuring quality of life, fatigue and
anorexia while on dialysis and we will then measure
hand grip strength, mid upper arm circumference, skin
fold thickness and complete Bioelectrical Impedance
Analysis (BIA) immediately post-dialysis. It is expected
these assessments with take 15 min to complete. Inclu-
sion criteria requires a confirmed diagnosis of stage 5
CKD (estimated GFR <15mL/min/1.73m2) receiving dia-
lysis, over the age of 18 and able to read and write. Ex-
clusion criteria involves those who are Stage 1-4 CKD,
Stage 5 CKD who are not receiving haemodialysis, lack-
ing capacity to give consent, under the age of 18 or non-
english speaking.
Study withdrawal
Participants will be advised of the voluntary nature of
their inclusion in this research and can withdraw from
follow-up at their request. As stated within the informa-
tion sheet, for any patient who does withdraw, we will
use collected data up to the withdrawal point (with the
participant’s consent) and this may be used for analysis.
We will record all reasons for patient withdrawal during
the data collection of this study.
Instruments
Within this study we will use the World Health
Organization’s (WHO) definition of quality of life which
is “individuals’ perception of their position in life in the
context of the culture and value systems in which they
live and in relation to their goals, expectations, stan-
dards and concerns”. The tool we will use to measure
quality of life will be the Kidney Disease Quality of Life
instrument Short Form- KDQOL-SF36 [12]. This tool
has been selected as it has confirmed reliability and val-
idity in measuring quality of life in an end stage renal
disease population [2]. The FACIT-fatigue scale, will be
used to measure fatigue. It has proven psychometrics
and is time efficient to complete and suitable to use for
the purposes proposed [4]. We will also measure an-
orexia using the Functional Assessment of Anorexia/
Cachexia Therapy (FAACT) questionnaire which is a
validated appetite assessment tool for patients receiving
dialysis [15].
Analysis
This is a small scale longitudinal study. The data col-
lected will provide information on ESKD participants
who do and do not exhibit known characteristics of
cachexia. The goal is to recruit and follow a population
of ESKD patients who are receiving haemodialysis for 1
year (or until death) to identify those who exhibit char-
acteristics of cachexia, to what degree, and to compare
them to those without cachexia. The findings from this
study will inform a disease-specific definition for cach-
exia in the ESKD population. Summary statistics will be
calculated regarding the characteristics of participants.
Analysis will be done comparing combinations of criteria
(Table 1) and their outcomes using multivariate logistic
regression and compare time to death with an age and
sex matched parallel cohort of ESKD participants receiv-
ing haemodialysis without weight loss and associated
characteristics of cachexia. Analysis of raw bioelectrical
impedance data will be undertaken to estimate nutri-
tional status and presence of a cachexia phenotype. Con-
version of impedance readings into fat free mass, raw
analysis by bioelectrical impedance vector analysis and
bioelectrical impedance phase angle assessment will be
undertaken. The longitudinal data collected will be ana-
lysed to develop a model potentially based on mortality
and which factors best associate with this. This will then
be prospectively tested in future studies.
Ethical considerations
This study will be conducted in compliance with Good
Clinical Practice Guidelines. Governance approval for the
study has been obtained from the host institution and the
Office of Research Ethics Committees Northern Ireland
(ORECNI) approval has been gained in preparation
for the study commencing (REC reference: 16/NI/0233).
Fundamental principles of good practice including the
provision of user friendly information sheets, informed con-
sent, voluntary participation, confidentiality and data protec-
tion procedures will be applied as a minimum standard
within this study. Professional gatekeepers will establish pri-
mary contact with potential participates about this study. It
is acknowledged that participants may find completion of
questionnaires distressing and a distress protocol has been
designed to manage such distress. The study is designed so
that it will not be over burdensome for participants. For ex-
ample, the validated tools can be completed whilst on dialy-
sis, we will access routine clinical information were we can
(bloods and weight post dialysis). All measures of lean
muscle mass will be collected post-dialysis and we will ad-
here to the manualized techniques for the instruments used.
Patient and public involvement (PPI) in this research
Members of the research team are also members of the
Northern Ireland Kidney Patient Association (NIKPA)
(JR, HN, PM, JS), Northern Ireland Kidney Research Fund
(PM, JS) and the British Kidney Patient Association (HN).
The NIKPA hold monthly meetings and are in regular e-
mail contact with members. The programme of renal
cachexia work has been discussed since inception with the
NIKPA and had been presented to their members, by
the lead researcher (JR), facilitated by an NIKPA
member. The Northern Ireland Kidney Research Fund
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fully support the planned research and members have been
able to discuss the proposal with the study team and have
made practical suggestions to improve its design, such as
the use of the term cachexia in patient facing material.
Members of these organisations have actively contributed
to the study proposal and have been influential in shaping
its scope. Our patient and public involvement organisa-
tions were represented at our September 2014 “Defining
Renal Cachexia” workshop led by the authors. A British
Kidney Patient Association representative was a speaker at
this workshop. Two NIKPA members were attendees and
actively engaged with workshop discussions.
Discussion
From this research we will identify the characteristics of
cachexia in an ESKD population receiving haemodialysis.
This predictive profile will require prospective valid-
ation, which will be done through further research with
a larger population. The findings from this study will be
used as pilot clinical data to inform a larger multi-site
study to develop a consensus definition for ESKD pa-
tients who have cachexia and test a treatment modality
aimed at improving morbidity and mortality. Establish-
ing a clinical phenotype and in turn a consensus defin-
ition for renal cachexia will allow for early recognition
and identification of the syndrome. Developing a con-
sensus definition will allow future research to be de-
signed which aims to develop and test targeted
interventional strategies aimed at improving both quality
of life and morbidity in patients on haemodialysis. This
in turn will help to standardise holistic care to this client
group through the development of patient centred care
guidelines and patient care pathways. It is acknowledged
that research with palliative populations faces particular
challenges as the patient’s condition deteriorates. The re-
search team has extensive experience working with such
populations [18, 19, 23, 24].
In planning this study the research team has
worked closely with clinical colleagues to ensure that:
data collection points will coincide with planned
dialysis; and routine clinical data already available
(such as monthly blood tests performed in all haemo-
dialysis patients as part of their standard care) will be
used to minimize any potential additional burden to
patients. We do expect deaths within the sample
population; most recent data (2010–2015) from the
recruiting regional nephrology unit, indicates an an-
nual mortality of 16% for patients with ESKD receiv-
ing maintenance haemodialysis.
Cachexia within a renal population may be an indica-
tor of poor prognosis, as is the case in other chronic
illnesses [3]. A robust definition of cachexia in ESKD is
a pre-requisite for researchers and clinical teams to
allow them to study and test interventions that can
improve both the quality of life and survival of individ-
uals with this condition.
Conclusions
There is no doubt that the clinical management of cach-
exia in persons with chronic kidney disease is challen-
ging due to the polysymptomatic nature of cachexia.
However to date, limited attention has been devoted to
cachexia in end stage kidney disease [14, 29]. For renal
cachexia, there are no standardized definitions or inclu-
sion criteria to help inform practice or research [25].
The importance of identifying the disease specific key
features of cachexia is evident in the cancer population,
where such work has allowed the biopsychosocial impact
of this syndrome to be researched and potential thera-
peutic inventions trialled [22].
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